Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

Gil I. Wolfe, Richard J. Barohn, Barbara M. Foster, Carlayne E. Jackson, John T. Kissel, John W. Day, Charles A. Thornton, Sharon P. Nations, Wilson W. Bryan, Anthony A. Amato, Miriam L. Freimer, Gareth J. Parry

Research output: Contribution to journalArticlepeer-review

79 Scopus citations


We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed.

Original languageEnglish (US)
Pages (from-to)549-552
Number of pages4
JournalMuscle and Nerve
Issue number4
StatePublished - Oct 1 2002


  • Clinical trials
  • Intravenous immunoglobulin
  • Myasthenia gravis
  • Treatment

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis'. Together they form a unique fingerprint.

Cite this